# Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

> **NCT05387785** · PHASE1 · UNKNOWN · sponsor: **Angion Biomedica Corp** · enrollment: 20 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** ANG-3070
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05387785
- **Lead sponsor:** Angion Biomedica Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387785, "Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05387785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*